2005
Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET)
Cartmel B, Dziura J, Cullen MR, Vegso S, Omenn GS, Goodman GE, Redlich CA. Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET). European Journal Of Clinical Nutrition 2005, 59: 1173-1180. PMID: 16015255, DOI: 10.1038/sj.ejcn.1602229.Peer-Reviewed Original ResearchMeSH KeywordsAntioxidantsAsbestosCardiovascular DiseasesCarotenoidsCholesterolDouble-Blind MethodFemaleHumansMaleMiddle AgedRisk FactorsSmokingTriglyceridesVitamin AConceptsRetinol Efficacy TrialPlacebo armSerum triglyceridesTriglyceride concentrationsEfficacy trialsVitamin ASerum cholesterol concentrationActive intervention armsActive intervention groupNational Cancer InstituteCardiovascular deathPlacebo groupCardiovascular mortalitySerum lipidsTotal cholesterolIntervention armSerum cholesterolVanguard StudyLung cancerIntervention groupCardiovascular diseaseCancer InstituteCholesterol concentrationsActive armBeta carotene
1999
Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET)
Redlich C, Chung J, Cullen M, Blaner W, Van Bennekum A, Berglund L. Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET). Atherosclerosis 1999, 145: 425-432. PMID: 10488974, DOI: 10.1016/s0021-9150(99)00266-x.Peer-Reviewed Original ResearchConceptsSerum triglyceride levelsHigh-density lipoproteinActive treatment groupLDL cholesterol levelsTriglyceride levelsCancer chemoprevention trialsCholesterol levelsSmall nonsignificant increaseCARET participantsCardiovascular mortalityTreatment groupsNonsignificant increaseLow-density lipoprotein cholesterol levelsLung cancer chemoprevention trialsRetinol Efficacy TrialActive treatment armsLipoprotein cholesterol levelsLung cancer mortalityLong-term supplementationActive intervention groupTreatment-induced changesSerum lipidsChemoprevention trialsHDL cholesterolActive treatment